Filings monitor · EW

What Edwards Lifesciences Corp's SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Income Tax Rate Changes89 · importance in its document · 10-Q · 2026Q3
   The effective income tax rate for the nine months ended September 30, 2026 rose to 31.2% from 16.1% in 2025, an increase of 15.1 percentage points. A $174.4 million valuation allowance against deferred tax assets was recorded in the…
2. Guidance / Outlook79 · importance in its document · 8-K exhibit · 4 Nov 2026
   Edwards raised its full-year 2026 sales growth guidance to approximately 11.5%, from 10% to 11%, and TAVR growth guidance to 9.0%–9.5%, from 8%–9%. TMTT sales guidance increased to $780–$790 million from $760–$780 million, while adjusted…
3. Intangible Asset Impairment77 · importance in its document · 10-Q · 2026Q3
   Edwards recorded $220.2 million of intangible and long-lived asset impairment charges in the three and nine months ended September 30, 2026. The charges primarily reflected the full impairment of an in-process research and development…
4. End-Market Demand Trends70 · importance in its document · 10-Q · 2026Q3
   For the first nine months of 2026, TAVR net sales increased 11.1% year over year, primarily on higher sales of the Edwards SAPIEN platform, particularly SAPIEN 3 Ultra RESILIA. TMTT sales rose 47.7%, driven by PASCAL TEER, EVOQUE…
5. Tax Litigation and Exposure64 · importance in its document · 10-Q · 2026Q3
   The IRS is pursuing material transfer-pricing adjustments concerning Surgical/TAVR intercompany transactions between Edwards’ United States and Switzerland subsidiaries. For tax years 2015–2017, the IRS sought $269.3 million in additional…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

• Income Tax Rate ChangesImportance 89
  The effective income tax rate for the nine months ended September 30, 2026 rose to 31.2% from 16.1% in 2025, an increase of 15.1 percentage points. A $174.4 million valuation allowance against deferred tax assets was…
• Intangible Asset ImpairmentImportance 77 · +1 more on this subject
  Edwards recorded $220.2 million of intangible and long-lived asset impairment charges in the three and nine months ended September 30, 2026. The charges primarily reflected the full impairment of an in-process research…
• End-Market Demand TrendsImportance 70
  For the first nine months of 2026, TAVR net sales increased 11.1% year over year, primarily on higher sales of the Edwards SAPIEN platform, particularly SAPIEN 3 Ultra RESILIA. TMTT sales rose 47.7%, driven by PASCAL…
• Tax Litigation and ExposureImportance 64
  The IRS is pursuing material transfer-pricing adjustments concerning Surgical/TAVR intercompany transactions between Edwards’ United States and Switzerland subsidiaries. For tax years 2015–2017, the IRS sought $269.3…
• Capital Return ProgramImportance 58
  During the nine months ended September 30, 2026, Edwards repurchased 8.5 million shares for $696.6 million under its Board-authorized program. The purchases included a $500.0 million accelerated share repurchase…
• Revenue Performance and MixImportance 54
  Net sales for the nine months ended September 30, 2026 increased 13.5% to $5,105.1 million from $4,498.0 million, a $607.1 million gain. TAVR sales rose 11.1% to $3,697.2 million, TMTT sales rose 47.7% to $583.2…
• Acquisition / Partnership / DivestitureImportance 52
  Edwards acquired Autus Valve Technologies in February 2026 for total consideration of $128.9 million, including $35.1 million in cash funded from existing cash. Contingent payments for Autus may reach $132.5 million…
• Operating Cash Flow and CapexImportance 47
  Operating cash flow for the nine months ended September 30, 2026 was $1,266.0 million, up $121.7 million from the prior-year period, primarily because tax payments were lower, partly offset by higher working-capital…
• Medicare TAVR Coverage ExpansionImportance 44
  In September 2026, the Centers for Medicare & Medicaid Services updated its National Coverage Determination for transcatheter aortic valve replacement (TAVR). The change expands Medicare coverage to certain…
• Geographic Market CommentaryImportance 42
  For the first nine months of 2026, sales increased 11.9% in the United States, 17.0% in Europe, 4.4% in Japan, and 19.3% in Rest of World. Outside the United States, sales grew 15.8% overall. In the third quarter, Rest…
• Product Launch and TransitionImportance 38
  Edwards received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system, intended for pediatric and adult patients with congenital heart disease. In TMTT, the company received CE…
• Liquidity and Debt PositionImportance 37
  At September 30, 2026, cash and cash equivalents and short-term investments totaled $4.1 billion in the United States and $511.0 million outside the United States. Edwards had no borrowings under its $750.0 million…

8-K filings last 12 months

• Guidance raised4 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “Increasing total company sales 2 growth guidance to approximately 11.5% from 10% to 11%”
  Read from the attached exhibit: Guidance / Outlook · Income Tax Rate Changes · VIE Investment Impairment
• Management change (filing not read)28 Aug 2026 · 8-K Item 5.02 · Routine · rule score 20
• Results (release not read)23 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
• Management change (filing not read)8 May 2026 · 8-K Item 5.02 · Routine · rule score 20
• Executive pay change4 May 2026 · 8-K Item 5.02 · Routine · rule score 5
  “On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026,…”
• Results (release not read)23 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)10 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 4 Aug 2026
  Tax Litigation and Exposure · End-Market Demand Trends · Operating Cash Flow and Capex

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.